Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Psychopharmacology (Berl). 2016 Apr 13;233(12):2399–2410. doi: 10.1007/s00213-016-4291-0

Table 2.

MEM effect on MCCB performance

MCCB cognitive domain T-score All subjects
Main analysis with diagnosis, dose, and test order as between-subject factor
 Diagnosis (Dx) F = 56.17, df (1,72), p < 0.0001
 Drug F = 12.26, df (1,72), p = 0.0008
 Domain F = 16.23, df (6, 432), p < 0.0001
 Dose F < 1
 Test order F < 1
 Dose × test order F = 4.09, df (1,72), p < 0.05
 Drug × dose F = 8.73, df (1,72), p = 0.004
 Drug × test order F = 85.74, df (1,72), p < 0.0001
 Domain × Dx F = 4.57, df (6, 432), p = 0.0002
 Drug × dose × test order F = 5.45, df (1,72), p < 0.05
 Drug × domain × dose F = 3.06, df (6, 432), p = 0.006
 Drug × domain × test order F = 16.39, df (6, 432), p < 0.0001
 Drug × domain × test order × Dx F = 2.09, df (6, 432), p = 0.05
MCCB composite T-score All subjects
Main analysis with diagnosis, dose, and test order as between-subject factors
 Dx F = 55.71, df (1,72), p < 0.0001
 Drug F < 1
 Drug × test order F = 39.58, df (1,72), p < 0.0001
 Drug × dose F = 4.15, df (1,72), p < 0.05
OCME cognitive domain T-score All subjects
Main analysis with diagnosis and dose as between-subject factor
 Diagnosis F < 1
 Dose F = 7.84, df (1,76), p = 0.006
 Domain × dose F = 2.51, df (6, 456), p = 0.02